Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Vanderbilt Advances Biotech Partnerships

by Michael McCoy
September 26, 2011 | A version of this story appeared in Volume 89, Issue 39

Vanderbilt University’s Center for Neuroscience Drug Discovery is advancing work with nonacademic partners. Vanderbilt has licensed compounds to Boston-based Karuna Pharmaceuticals for development as potential schizophrenia treatments. Compounds developed under a three-year-old partnership with Seaside Therapeutics of Cambridge, Mass., are now undergoing final preclinical studies as treatments for fragile X syndrome, the most common genetic cause of autism. And a potential Parkinson’s disease treatment developed with the Michael J. Fox Foundation is also advancing toward the clinic.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.